Cheng Zhang, CEO of Character Biosciences (Character)

Ge­nomics biotech un­der­goes a facelift, re­brand­ing from Clover to Char­ac­ter Bio­sciences

Though Clover Ther­a­peu­tics has a new iden­ti­ty, CEO Cheng Zhang is mak­ing one thing clear: the ge­nomics out­fit’s goals and mis­sion re­main the same. Sim­ply put, “we’re dou­bling down on it,” Zhang tells End­points News.

The San Fran­cis­co biotech, orig­i­nal­ly fo­cused on an­a­lyz­ing reams of health­care and imag­ing da­ta to tack­le “dis­eases of ag­ing,” an­nounced its new name late Tues­day morn­ing: Char­ac­ter Bio­sciences. On top of that, the biotech an­nounced $18 mil­lion in new fund­ing via a Se­ries A round.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.